Hydrogen sulfide (H~2~S) has long been recognized as a toxic, colorless gas with a characteristic rotten-egg odor that is found in various natural and industrial products. However, recent accumulated data have demonstrated that H~2~S exerts a host of biological effects on various targets, ranging from cytotoxic to cytoprotective effects[@b1][@b2]. Among these effects is a steadily growing list of physiological functions in mammals that affect blood pressure, oxidative stress, inflammation, and insulin secretion. Endogenous H~2~S is produced enzymatically by the cysteine metabolic enzymes cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase[@b1]. The ability of H~2~S to function as a signaling molecule at low micromolar levels in mammalian systems parallels the action of another established gasotransmitter, nitric oxide (NO)[@b3]. In particular, H~2~S exhibits almost all of the beneficial cardiovascular effects of NO without the deleterious production of reactive oxygen species (ROS), acting instead as a scavenger of ROS. Other studies have indicated that the administration of the H~2~S donor sodium hydrosulfide (NaHS) could attenuate ischemia/reperfusion (I/R) injury in the heart, liver, and kidneys by opening K~ATP~ channels[@b4][@b5]. Transplantation of exogenous H~2~S-pretreated mesenchymal stem cells (MSCs) reduced infarct size and increased left ventricular function in a rat myocardial infarction (MI) model[@b6]. These studies suggest that NaHS has anti-inflammatory effects and modulates innate immune cells[@b7][@b8].

Undifferentiated monocytes in the red pulp of the spleen are activated and migrate to areas of tissue that have suffered ischemic myocardial injury[@b9]. CD11b^+^Gr-1^+^ myeloid cells are among the immunosuppressive cells in the spleen and bone marrow[@b10]. In conditions with multiple inflammatory stimuli, such as DSS-induced colitis and TPA-induced skin inflammation, the number of CD11b^+^Gr-1^+^ myeloid cells is markedly increased in the circulation, as these cells are released from the spleen and bone marrow to perform related immune functions[@b11].

In the present study, we used a murine MI model to test the hypothesis that the administration of NaHS pre- and post-coronary artery occlusion could protect the heart from myocardial injury and improve survival; we further explored the mechanism of NaHS-mediated cardioprotection, specifically the regulation of CD11b^+^Gr-1^+^ myeloid cells and Bax/Bcl-2 apoptotic signaling. The findings provided a novel insight into the cardioprotective role of H~2~S in the pathophysiology of MI and the post-MI immune response, and they improved our understanding of clinical therapies for the cardiovascular system.

Results
=======

NaHS improves survival
----------------------

The survival was 100% in the sham-operated mice, while 29 of 32 (91%) mice in the MI + NaHS group survived, compared with 21 of 32 (66%) in the MI + Saline group ([Fig. 1](#f1){ref-type="fig"}). The causes of death in each group are summarized in [Table 1](#t1){ref-type="table"}. The most frequent cause of post-MI death in both MI groups was ventricular rupture (45% in MI + Saline versus 33% in MI + NaHS), which occurred within 24 hrs post-MI.

NaHS preserves left ventricular function after MI
-------------------------------------------------

Acute MI in mice causes a myriad of hemodynamic stresses, which trigger left ventricular remodeling and eventually lead to functional decompensation and heart failure. To evaluate the effects of exogenous H~2~S on the left ventricular function of the mice with MI, the surviving animals were evaluated with two-dimensional, high-resolution echocardiography ([Fig. 2A](#f2){ref-type="fig"}). None of the groups presented significant LV dilatation at 24 hrs after infarction ([Fig. 2B](#f2){ref-type="fig"}). However, the mice that were treated with NaHS displayed a significantly decreased LV end-systolic diameter ([Fig. 2C](#f2){ref-type="fig"}) and a more preserved ejection fraction ([Fig. 2D](#f2){ref-type="fig"}), compared with the MI + Saline mice.

NaHS limits the myocardial infarct size
---------------------------------------

Representative photomicrographs of mid-ventricular cross-sections of TTC-stained hearts are shown in [Fig. 3A](#f3){ref-type="fig"}. Consistent with the improvement in cardiac function ([Fig. 2](#f2){ref-type="fig"}), the photomicrographs show a smaller infarct size (% of left ventricular) at 24 hrs after infarction ([Fig. 3B](#f3){ref-type="fig"}) in the NaHS-treated group.

NaHS improves H~2~S levels in post-MI cardiac tissue
----------------------------------------------------

Next, we determined whether an exogenous H~2~S donor could affect the H~2~S levels in cardiac tissue that was under ischemic stress. [Fig. 4](#f4){ref-type="fig"} illustrates a significant decrease in H~2~S in the injured myocardium, compared with the sham group (P \< 0.01). However, treatment with NaHS mitigated the decrease in H~2~S that was seen in the MI + Saline group (P \< 0.01), showing no difference compared with the sham group (P \> 0.05).

Cardiac tissue H~2~S inhibits the post-MI recruitment of CD11b^+^Gr-1^+^ myeloid cells
--------------------------------------------------------------------------------------

To elucidate the effects of H2S on immune activation and infiltration into the infarcted heart, we quantified the immune cells in the heart with the myeloid cell surface markers CD11b and Gr-1. FACS analysis showed that CD11b^+^Gr-1^+^ myeloid cells were significantly increased in the heart after infarction, compared with the sham group (P \< 0.01). However, NaHS treatment significantly reduced the recruitment of CD11b^+^Gr-1^+^ myeloid cells seen in the MI + Saline group ([Fig. 5B](#f5){ref-type="fig"}).

Cardiac tissue H~2~S reduces post-MI cardiomyocyte apoptosis *in vivo*
----------------------------------------------------------------------

Immunoblots revealed that the expression of Bax was significantly reduced, while Bcl-2 expression was increased in the hearts following 24 hrs of treatment with NaHS, compared to the expression levels in the MI + Saline group ([Figs. 6B and 6C](#f6){ref-type="fig"}). Consequently, the ratio of Bcl-2 to Bax was increased in the MI + NaHS mice, compared with the MI + Saline mice ([Fig. 6D](#f6){ref-type="fig"}). This result was confirmed using another apoptotic marker, activated caspase 3 ([Fig. 6E](#f6){ref-type="fig"}). Consistent with the known roles of Bax and Bcl-2 in apoptosis, the percentage of TUNEL-positive (apoptotic) cardiomyocytes in the infarcted heart was lower in animals treated with NaHS than in the MI + Saline mice ([Figs. 6F and 6G](#f6){ref-type="fig"}).

NaHS inhibits the migration of CD11b^+^Gr-1^+^ myeloid cells
------------------------------------------------------------

To gain further insight into the relationship between H~2~S and CD11b^+^Gr-1^+^ myeloid cells in this MI model, we determined the numbers of CD11b^+^Gr-1^+^ myeloid cells in the peripheral blood and the spleen. We found that the number of myeloid cells significantly increased in the blood after infarction ([Fig. 7B](#f7){ref-type="fig"}). Administration of H~2~S, however, reduced the number of circulating CD11b^+^Gr-1^+^ myeloid cells, compared with the number seen in the MI + Saline group. Additionally, NaHS resulted in more CD11b^+^Gr-1^+^ myeloid cells in the reservoir spleen of MI + NaHS, compared with MI + Saline ([Fig. 7D](#f7){ref-type="fig"}).

NaHS reduces post-MI inflammation
---------------------------------

To investigate the effects of NaHS on the inflammatory response, the serum levels of TNFα and IL-1β were measured at 24 hrs post-MI. ELISA analysis revealed significant increases in both TNFα and IL-1β in the MI + Saline group, compared with the sham group ([Figs. 8A and 8B](#f8){ref-type="fig"}). However, NaHS treatment mitigated the increases in TNFα and IL-1β levels that were seen in the MI + Saline group (41.2 ± 4.1 versus 53.0 ± 4.7 pg/mL, 162.0 ± 19.1 versus 267.2 ± 25.2 pg/mL, respectively).

Discussion
==========

Left ventricular remodeling after acute MI causes heart failure, which is an epidemic with high mortality and an increasing prevalence. Despite advances in medical and interventional therapy for MI that have dramatically improved survival rates, many surviving patients continue to develop heart failure[@b12]. Emerging evidence from experimental models of myocardial ischemia has suggested that defects in the timely suppression, resolution, and containment of post-infarction inflammatory responses result in adverse remodeling of the infarcted heart[@b13][@b14]. A recent study in a mouse model reported substantial changes in the immune response dynamics after permanent (MI) or transient (IR) ligation of the left anterior descending artery[@b15][@b16]. Inflammation signals recruit neutrophils to the infarcted zone within 24 hrs, and the recruitment of monocytes/macrophages occurs shortly thereafter. In the infarcted myocardium, several innate immune pathways participate in the early steps of the inflammatory response following infarction, including pathways that involve the membrane-bound Toll-like receptors (TLRs), the high-mobility group box 1, and the complement system. Understanding the "STOP" signals involved in suppression of inflammation following infarction might be the key to preventing adverse remodeling and progression to heart failure[@b13][@b17].

As a gasotransmitter, H~2~S is able to diffuse freely across cell membranes in a receptor-independent manner and to activate various cellular signals that modulate metabolism, cardiac function, and cell survival. These distinct abilities make H~2~S an attractive pharmacological agent for the treatment of cardiovascular disease[@b18]. Several experimental approaches have shown that increased levels of H~2~S exert cyto- and cardioprotective effects in the injured myocardium. The results can be achieved both by increasing the endogenous amount of H~2~S and by adding exogenous H~2~S (the most commonly used H~2~S donors are NaHS and Na~2~S)[@b19][@b20]. Specifically, cardiac-restricted overexpression of CSE resulted in increased H~2~S bioavailability and elicited a cardioprotective response to ischemic heart failure and acute myocardial I/R injury[@b21]. In contrast, decreased production of this molecule has been associated with increased myocardial damage[@b22][@b23]. In this study, our results indicated that NaHS could attenuate myocardial ischemic injury, preserve left ventricular function, and enhance survival following infarction.

Because CD11b^+^Gr-1^+^ myeloid cells are among the primary immunosuppressive factors in cancer and other pathological conditions, several different therapeutic strategies that target these cells are currently being explored[@b24][@b25]. Although the studies described were undertaken in tumor-bearing hosts, it is likely that similar strategies aimed at inhibiting or eliminating CD11b^+^Gr-1^+^ myeloid cells will be therapeutically useful in other pathological conditions. In previous studies, the balance of histamine within the tumor microenvironment was found to be a critical factor, and CD11b^+^Gr-1^+^ myeloid cells represented an important therapeutic target for the control of cancer growth[@b11]. An increasing amount of evidence has indicated that CD11b^+^Gr-1^+^ myeloid cells play an important role in physiological and pathological conditions. Related research reported that myocardial I/R induced a surge in CD11b^+^Gr-1^+^ neutrophil recruitment to the myocardium, and treatment with anti-IL-17A mAb reduced this effect[@b26]. In the current study, we found that NaHS could protect against ischemic myocardial injury by reducing the recruitment of CD11b^+^ Gr-1^+^ myeloid cells to the myocardium, inhibiting the migration of these cells from the splenic reservoir, and decreasing the induced expression of TNFα and IL-1β in the serum following ischemic injury.

Both permanent coronary occlusion and I/R caused large amounts of myocytes and nonmyocytes to undergo apoptosis within the ischemic zone[@b27][@b28]. This excessive or inappropriate apoptosis contributed to pathological changes in the heart. The cardioprotective effects of H~2~S in the setting of myocardial I/R in mice were reportedly mediated in large part by a combination of antioxidant and anti-apoptotic signaling[@b29]. In addition to its well-known immunosuppressant properties, cyclosporine is a potent inhibitor of mitochondrial permeability transition pore opening, which is an important step in programmed cell death. In a small pilot trial of 58 patients with acute ST-elevation myocardial infarction, an intravenous bolus of cyclosporine immediately before percutaneous coronary intervention was associated with a smaller infarct than that seen with placebo[@b30]. Neutrophil recruitment played a major role in myocardial damage after ischemia injury[@b31]. In the present study, H~2~S inhibited the recruitment of CD11b^+^Gr-1^+^ myeloid cells to the myocardium and attenuated the post-MI inflammatory response. Our results also revealed that H~2~S reduced the expression level of the pro-apoptotic protein Bax and induced the expression of the anti-apoptotic protein Bcl-2, therefore causing an increase in the ratio of Bcl-2/Bax, as confirmed by the change in caspase 3 activity, and resulting in fewer TUNEL-positive (apoptotic) cardiomyocytes.

In fact, moderate use of H~2~S balneotherapy (treatment by bathing) has been shown to raise tolerance to exercise and reduce the daily need for short-acting nitrates in patients with coronary artery disease[@b32]. Moreover, recent clinical data have suggested that total plasma sulfide levels are negatively correlated with the severity of congestive heart failure and that low total plasma sulfide levels predict higher mortality[@b33]. The current study shows that NaHS, when administered to mice in two separate doses, significantly enhances the generation of H~2~S in cardiac tissue, reduces inflammation, attenuates left ventricular dysfunction 24 hrs after ischemic myocardial injury, and hence improves survival.

In conclusion, we demonstrated that NaHS has potent anti-inflammatory and anti-apoptotic effects in heart subjected to acute MI *in vivo*. These cardioprotective functions of NaHS are secondary to a combination of anti-inflammatory and anti-apoptotic effects. Moreover, the anti-inflammatory function may be in part due to the limitation of the recruitment of CD11b^+^Gr-1^+^ myeloid cells. Additional insight into the control of CD11b^+^Gr-1^+^ myeloid cells by H~2~S treatment will not only illuminate the fundamental molecular principles of CD11b^+^Gr-1^+^ myeloid cells regulation but will facilitate the therapeutic value in the clinical setting of myocardial ischemia injury.

Methods
=======

Animals
-------

C57BL/6J mice (20--25 g, male, 8--10 weeks; Slac Laboratory, Shanghai, China) were housed under standard conditions in an animal room with a 12/12 h day/night cycle with free access to water and food. This study was performed in strict accordance with the recommendations from the Guide for Animal Management Rules from the Ministry of Health of the People\'s Republic of China. The protocol was approved by the Committee on the Ethics of Animal Experiments of Fudan University. All of the surgeries were performed under anesthesia, and the utmost effort was exerted to prevent suffering and minimize the numbers of mice required for each experiment.

H~2~S donor
-----------

H~2~S was administered in the form of NaHS, which was obtained from Sigma-Aldrich. NaHS was diluted in normal (0.9%) saline to the desired concentration immediately before administration.

Myocardial infarction protocol
------------------------------

Surgery to induce myocardial infarction was performed in the mice as described previously[@b34]. In brief, the mice were anesthetized by inhalation of isoflurane, were intubated with a 22-G intravenous catheter, and then were fully anesthetized with 1.0--2.0% isoflurane gas while being mechanically ventilated on a positive pressure ventilator. Left thoracotomy was performed at the fourth intercostal space, and the pericardium was stripped to expose the heart. The left descending coronary artery was identified and occluded with an 8--0 silk ligature that was placed around it. The success of the ligation was confirmed when the anterior wall of the left ventricle turned pale. The chest cavity was closed, and the animal was placed in a cage on a heating pad. Sham-operated mice underwent the same surgical procedures except that the suture placed under the left anterior descending artery was not tied.

Experimental groups
-------------------

Four groups were used: 1) Sham + Saline: each mouse received 1 mg/kg normal (0.9%) saline (i.p.) 5 minutes before surgery and 60 minutes after sham operation; 2) Sham + NaHS: mice received 1 mg/kg NaHS (i.p.) 5 minutes before surgery and 60 minutes after sham operation; 3) MI + Saline: 1 mg/kg normal (0.9%) saline was administered as in group 1; and 4) MI + NaHS: 1 mg/kg NaHS was administered as in group 2.

Survival
--------

The survival rate was measured based on the animals that survived the experimental protocol starting from recovery after surgery until 24 hrs after infarction. An autopsy was performed on each animal found dead or sacrificed after 24 hrs.

Echocardiography
----------------

Transthoracic echocardiography was performed using the Vevo 770 imaging system (VisualSonics, Inc.) 24 hrs after surgery. The mice were anesthetized with 1.0--2.0% isoflurane and placed on a heating pad to maintain their body temperatures. The left ventricular dimensions were quantified by digitally recorded two-dimensional short-axis M-mode tracings at the level of the papillary muscles, to allow for consistent measurement at the same anatomic location in different mice; at least three consecutive beats were evaluated. Left ventricular (LV) wall thickness and internal dimensions were measured, and the LV ejection fraction (LVEF) was calculated.

Infarct size assessment
-----------------------

After 24 hrs of ischemia, the infarct size was determined with triphenyltetrazolium chloride (TTC) staining. Briefly, the mice were sacrificed, and the hearts were removed and sliced into five 1.0-mm thick sections perpendicular to the long axis. The sections were then incubated with 1% TTC (Sigma) in a phosphate solution at 37°C for 15 min. The areas of infarcted tissue (TTC-negative staining area) and the whole left ventricle were determined by computer morphometry using Bioquant imaging software.

H~2~S levels in the cardiac tissue
----------------------------------

The tissue concentration of H~2~S was measured using a method described previously[@b35]. In brief, the mice were euthanized under anesthesia. The heart was flash-frozen with liquid nitrogen and then was homogenized in ice-cold potassium phosphate buffer. The homogenates were then centrifuged, and the supernatants were mixed with zinc acetate and water for 10 minutes at room temperature. Trichloroacetic acid was then added. The mixture was centrifuged, and the clear supernatant was collected and mixed with *N*, *N*-dimethyl-*p*- phenylenediamine sulfate and FeCl~3~. After 20 minutes, the absorbance at 670 nm was measured by a microplate reader (Infinite 200; TECAN). The calibration curve of absorbance versus H~2~S concentration was obtained using NaHS solutions at varying concentrations (0--320 μmol/L).

Flow cytometry analysis
-----------------------

A subset of six mice per group was used for flow cytometric analysis. The blood, spleen, and heart were collected and made into single-cell suspensions for flow cytometry, as previously described[@b11][@b34]. The cells were stained with a mixture of antibodies (anti-CD11b-FITC, anti-Gr-1-PerCP-Cy5.5; BD Biosciences). Data were acquired using an LSRII flow cytometer (BD Biosciences) and were analyzed with FlowJo7 software (Tree Star, Inc.).

Western blot
------------

Proteins were extracted in a RIPA buffer from the whole mouse heart, and an equal number of proteins (30 μg) from each sample was separated by SDS-PAGE and was transferred onto a PVDF membrane (Merck Millipore). The membrane was blocked and incubated with primary antibodies (Bax, Bcl-2 from Cell Signaling Technology; caspase 3 from Bioworld) overnight at 4°C, followed by corresponding horseradish peroxidase-conjugated secondary antibodies (Jackson Laboratory). The blots were visualized with enhanced chemiluminescence and were quantified by densitometry.

Cardiomyocyte apoptosis
-----------------------

Cardiomyocyte apoptosis was evaluated via the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, using the ApopTag Peroxidase in Situ Apoptosis Detection Kit (Merck Millipore) according to the protocol provided by the manufacturer. The apoptosis index was determined by counting TUNEL-positive nuclei in five different fields per section, and it is expressed as a percentage of the total nuclei.

Measurement of cytokines
------------------------

Blood was collected by cardiac puncture at the time of sacrifice. The samples were centrifuged, and the serum was collected according to the protocol provided by the manufacturer. The expressions of TNFα and IL-1β cytokines were measured with an ELISA Kit (R&D Systems).

Statistical analysis
--------------------

The data are expressed as means ± SEMs. Different groups were compared by one-way ANOVA, followed by Tukey\'s or Bonferroni post-hoc test when applicable. Comparisons between the two groups were assessed by the *t* test. The Chi-square test (or Fisher\'s exact test when appropriate) was used to compare discrete variables between different groups. A P value less than 0.05 was considered significant.
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![Survival of the mice in the different groups at 24 hrs post-MI.\
Note that the NaHS-treated MI mice exhibited a significant increase in survival compared with the MI + Saline animals.](srep04774-f1){#f1}

![Cardiac function measured by echocardiography at 24 hrs post-surgery.\
(A) Representative M-mode images from individual groups. (B--D) Left ventricular end-diastolic diameter (LVEDD), end-systolic diameter (LVESD), and ejection fraction (LVEF) were calculated for the different treatment groups (n = 8).](srep04774-f2){#f2}

![The infarct size measured at 24 hrs post-MI in the different groups.\
(A) Representative mid-myocardial cross-sections of TTC-stained hearts. White area, infarcted tissue; red, viable myocardium. (B) The infarcted size, expressed as a percentage of the left ventricle (n = 5--6).](srep04774-f3){#f3}

![NaHS therapy improves the level of H~2~S.\
Note that NaHS caused an increase in level of cardiac tissue H~2~S after infarction (n = 4--5).](srep04774-f4){#f4}

![NaHS inhibits the recruitment of CD11b^+^Gr-1^+^ myeloid cells.\
(A) Representative flow cytometry dot plots of the CD11b^+^Gr-1^+^ myeloid cells that infiltrated into the myocardium 24 hrs post-MI. (B) The percentage of CD11b^+^Gr-1^+^ cells that infiltrated into the myocardium (n = 6).](srep04774-f5){#f5}

![H~2~S reduces cardiomyocyte apoptosis *in vivo*.\
(A) Representative immunoblots showing the expression of Bax, Bcl-2, and activated caspase 3 p17 in the heart. Bax (B) and Bcl-2 (C) expression normalized to GAPDH (n = 6). (D) Densitometric analysis of the ratio of Bcl-2 to Bax. (E) Activated caspase 3 p17 expression normalized to GAPDH (n = 6). (F) Representative photomicrographs of heart sections showing TUNEL-positive (apoptotic) myocardiocytes (200×). (G) Quantification of the apoptotic cells (% total nuclei, n = 6).](srep04774-f6){#f6}

![NaHS inhibits the migration of CD11b^+^Gr-1^+^ myeloid cells.\
Representative flow cytometry dot plots of CD11b^+^Gr-1^+^ myeloid cells in the blood (A) and the spleen (C) 24 hrs post-MI. The percentage of CD11b^+^Gr-1^+^ cells in the blood (B, n = 6) and the spleen (D, n = 6).](srep04774-f7){#f7}

![NaHS inhibits the extent of inflammation.\
The TNFα (A) and IL-1β (B) levels were significantly decreased in mice treated with an NaHS donor 24 hrs after infarction (n = 6).](srep04774-f8){#f8}

###### Causes of death of mice that suffered from an MI

  Conditions             Sham + Saline   Sham + NaHS   MI + Saline   MI + NaHS
  --------------------- --------------- ------------- ------------- -----------
  Ventricular Rupture          0              0             5            1
  Acute Heart Failure          0              0             2            0
  Bleeding                     0              0             1            1
  Unknown Reasons              0              0             3            1
  Total Death                  0              0            11            3
